Literature DB >> 9858360

Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs.

D Moechars1, M Gilis, C Kuipéri, I Laenen, F Van Leuven.   

Abstract

Transgenic mouse strains were generated that overexpress human APP or clinical mutants of APP. All transgenic mouse strains that over-express APP displayed essentially the same phenotype of disturbed behaviour, differential glutamatergic responses, deficits in maintenance of long-term potentiation and premature death, but formation of amyloid plaques was seen in the highest expressing APP/London transgenic mice only. Apart from cognitive deficits, the APP transgenic mice were characterized by aggressive behaviour, which was pharmacologically alleviated with 8-OH-DPAT and buspirone, two serotonergic agonists. The atypical neuroleptic drug risperidone was equally active in this regard. The data establish an important aspect of the transgenic mice as experimental models for behavioural aspects of Alzheimer's disease, in addition to other early and late symptoms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858360     DOI: 10.1097/00001756-199811160-00004

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

1.  Neonatal administration of buspiron causes changes in intermale aggression of adult mice.

Authors:  N V Markina; O B Shilova; O V Perepelkina; O S Boyarshinova; I B Fedotova; F Z Bizikoeva; I V Gichenok; I I Poletaeva
Journal:  Dokl Biol Sci       Date:  2004 May-Jun

2.  Gene by Social-Environment Interaction for Youth Delinquency and Violence: Thirty-Nine Aggression-related Genes.

Authors:  Hexuan Liu; Yi Li; Guang Guo
Journal:  Soc Forces       Date:  2015

3.  Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

Authors:  Rinaldo Zurbriggen; Mario Amacker; Andreas R Kammer; Nicole Westerfeld; Peter Borghgraef; Fred Van Leuven; Ingrid Van der Auwera; Stefaan Wera
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1.

Authors:  I Dewachter; J Van Dorpe; L Smeijers; M Gilis; C Kuipéri; I Laenen; N Caluwaerts; D Moechars; F Checler; H Vanderstichele; F Van Leuven
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

5.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

6.  FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein.

Authors:  Lee Jae Morse; Sandra M Payton; Gregory D Cuny; Jack T Rogers
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression.

Authors:  Jared J Schwartzer; Randall L Morrison; Lesley A Ricci; Richard H Melloni
Journal:  Psychopharmacology (Berl)       Date:  2008-12-06       Impact factor: 4.530

8.  Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult.

Authors:  Shaefali P Rodgers; Heather A Born; Pritam Das; Joanna L Jankowsky
Journal:  Mol Neurodegener       Date:  2012-06-18       Impact factor: 14.195

9.  Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB.

Authors:  Véronique Brault; Benoît Martin; Nathalie Costet; Jean-Charles Bizot; Yann Hérault
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

10.  Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol.

Authors:  Sandra Payton; Catherine M Cahill; Jeffrey D Randall; Steven R Gullans; Jack T Rogers
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.